Literature DB >> 20179719

Heart failure: aldosterone antagonists are underused by clinicians.

Jane-Lise Samuel, Claude Delcayre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20179719     DOI： 10.1038/nrcardio.2009.244

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

1.  The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function.

Authors:  Sylvia A S Tait; James F Tait; John P Coghlan
Journal:  Mol Cell Endocrinol       Date:  2004-03-31       Impact factor: 4.102

2.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.

Authors:  Paul Milliez; Xavier Girerd; Pierre-François Plouin; Jacques Blacher; Michel E Safar; Jean-Jacques Mourad
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

3.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

4.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

5.  Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells.

Authors:  Marie-Lory Ambroisine; Julie Favre; Patricia Oliviero; Camille Rodriguez; Ji Gao; Christian Thuillez; Jane-Lise Samuel; Vincent Richard; Claude Delcayre
Journal:  Circulation       Date:  2007-11-05       Impact factor: 29.690

6.  Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling.

Authors:  An Di Zhang; Aurelie Nguyen Dinh Cat; Christelle Soukaseum; Brigitte Escoubet; Aïcha Cherfa; Smail Messaoudi; Claude Delcayre; Jane-Lise Samuel; Frederic Jaisser
Journal:  Hypertension       Date:  2008-11-03       Impact factor: 10.190

7.  The 45-year story of the development of an anti-aldosterone more specific than spironolactone.

Authors:  Joël Ménard
Journal:  Mol Cell Endocrinol       Date:  2004-03-31       Impact factor: 4.102

8.  Use of aldosterone antagonists in heart failure.

Authors:  Nancy M Albert; Clyde W Yancy; Li Liang; Xin Zhao; Adrian F Hernandez; Eric D Peterson; Christopher P Cannon; Gregg C Fonarow
Journal:  JAMA       Date:  2009-10-21       Impact factor: 56.272

9.  Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism.

Authors:  C G Brilla; L S Matsubara; K T Weber
Journal:  J Mol Cell Cardiol       Date:  1993-05       Impact factor: 5.000

Review 10.  Effects of aldosterone on coronary function.

Authors:  Ludovic Benard; Paul Milliez; Marie-Lory Ambroisine; Smail Messaoudi; Jane-Lise Samuel; Claude Delcayre
Journal:  Pharmacol Rep       Date:  2009 Jan-Feb       Impact factor: 3.024
  10 in total
  3 in total

Review 1.  Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage.

Authors:  Bharathi Upadhya; Patrick M Kozak; Richard Brandon Stacey; Ramachandran S Vasan
Journal:  Curr Hypertens Rep       Date:  2022-02-14       Impact factor: 5.369

Review 2.  Aldosterone receptor antagonists: current perspectives and therapies.

Authors:  Jason L Guichard; Donald Clark; David A Calhoun; Mustafa I Ahmed
Journal:  Vasc Health Risk Manag       Date:  2013-06-24

Review 3.  Interfering with mineralocorticoid receptor activation: the past, present, and future.

Authors:  Anne M Dorrance
Journal:  F1000Prime Rep       Date:  2014-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.